脂蛋白酯酶基因PvuⅡ多态与中国人高脂血症和冠心病的Meta分析

Meta-analysis of LPL PvuⅡ polymorphism with hyperlipoidemia and coronary heart disease in the Chinese population

国内多个研究报道了脂蛋白酯酶基因(LPL)PvuⅡ多态(rs285)与中国人高脂血症和冠心病的关系,但单个研究的样本量都较小(119～647),结果不尽一致。为了全面客观评价LPL基因PvuⅡ多态在中国人高脂血症和冠心病发病中的作用,文章对所有中国人群的研究进行了Meta分析。共11篇文献纳入研究,其中关于高脂血症的研究6项,包括患者943例,正常对照1093例,关于冠心病的研究5项,包括患者821例,正常对照727例。入选研究无明显的发表偏倚,但经同质性检验存在明显的异质性。Meta分析结果显示LPLPvuⅡ多态的P+等位基因增加高脂血症的患病风险(OR=1.36,95%CI1.07～1.73,P=0.011),但与冠心病相关不显著(P=0.755)。因此,文章结果表明LPL基因PvuⅡ多态与中国人高脂血症易感性相关联,与冠心病关联不显著。

Multiple studies reported the association of LPL PvuⅡpolymorphism（rs285） with hyperlipoidemia and coronary heart disease in the Chinese population;however,the sample sizes of these studies were small（119-647） and the results were not consistent.A Meta-analysis was undertaken to evaluate the role of LPL PvuⅡpolymorphism in hyperlipoidemia and coronary heart disease in Chinese.A total of 11 case-control studies were collected.Among them,6 studies on hyperlipoidemia contained 943 cases and 1,093 controls,and 5 studies on coronary heart disease contained 821 cases and 727 controls.No significant publication bias was found and significant heterogeneity between these studies was observed.The results of Meta-analysis indicated that the allele P＋ increased the risk of hyperlipoidemia（OR=1.36,95%CI 1.07-1.73,P=0.011）,and no evidence of association（P=0.755） was found for coronary heart disease.Our study suggested that the LPL PvuⅡpolymorphism was significantly associated with hyperlipoidemia but not with coronary heart disease in the Chinese population.